KPI data tables

CSL operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.

CSL Behring Revenue by Therapy (Annual) (USD millions)
PeriodImmunoglobulinsAlbuminHaemophiliaHereditary angioedemaPeri-operative bleedingOther Behring
FY 20266,2481,1151,515884834754
FY 20256,0641,2971,488760913598
FY 20245,6661,2091,3137331,023625

Source: CSL Annual Report 2026 Note 2 operating revenue by product or service category (https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2026.pdf): FY 2026 / FY 2025 immunoglobulins 6,248 / 6,064, albumin 1,115 / 1,297, haemophilia 1,515 / 1,488, hereditary angioedema 884 / 760, peri-operative bleeding 834 / 913, other 754 / 598. Annual Report 2025 Note 2 (https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2025.pdf) restates FY 2024: immunoglobulins 5,666, albumin 1,209, haemophilia 1,313, hereditary angioedema 733, peri-operative bleeding 1,023, other 625. FY 2026 results presentation Appendix A (https://investors.csl.com/pdf/3d18fc4f-6133-41c7-9188-ec992e930ca3/Platform/ListPage/CSL-Results-Presentation-for-FY2026.pdf) matches the FY 2026 therapy totals.

CSL Behring IVIG vs SCIG Revenue (Annual) (USD millions)
PeriodIVIGSCIG
FY 20264,0812,167
FY 20253,9862,078
FY 20243,7051,961
FY 20233,0281,647

Source: CSL full-year results presentation, Behring revenue-by-therapy-group pies. FY 2026 Appendix A (https://investors.csl.com/pdf/3d18fc4f-6133-41c7-9188-ec992e930ca3/Platform/ListPage/CSL-Results-Presentation-for-FY2026.pdf): IVIG 4,081, SCIG 2,167. FY 2025 (https://investors.csl.com/pdf/c72789c6-778d-4b88-8657-be40cf97e2b3/CSL-Results-Presentation.pdf): IVIG 3,986, SCIG 2,078. FY 2024 (https://investors.csl.com/pdf/78576f85-4598-455b-80c1-16c391c56445/Results-Presentation.pdf?Platform=ListPage): IVIG 3,705, SCIG 1,961. FY 2023 (https://investors.csl.com/pdf/5180b107-7849-4ad4-aeaf-8092e62b4bb6/CSL-Results-Presentation.pdf): IVIG 3,028, SCIG 1,647. Statutory immunoglobulin totals in Annual Report Note 2 match the IVIG plus SCIG sum each year (https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2026.pdf).

CSL Revenue by Business (Annual) (USD millions)
PeriodCSL BehringCSL SeqirusCSL Vifor
FY 202611,3872,0312,379
FY 202511,1582,1662,234
FY 202410,6082,1282,064
FY 20239,2902,0311,989

Source: CSL Annual Report 2026, segment note, total segment revenue (https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2026.pdf): FY 2026 / FY 2025 Behring 11,387 / 11,158, Vifor 2,379 / 2,234, Seqirus 2,031 / 2,166, group 15,797 / 15,558. Annual Report 2025 segment note (https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2025.pdf) restates FY 2025 / FY 2024. Annual Report 2024 / FY 2024 statutory accounts segment note (https://investors.csl.com/pdf/457c4fdb-099e-4e72-8917-fd3c8c0b4b96/Full-Year-Statutory-Accounts-for-30-June-2024.pdf): FY 2024 / FY 2023 Behring 10,608 / 9,290, Seqirus 2,128 / 2,031, Vifor 2,064 / 1,989, group 14,800 / 13,310. FY 2026 results presentation (18 Aug 2026, https://investors.csl.com/pdf/3d18fc4f-6133-41c7-9188-ec992e930ca3/Platform/ListPage/CSL-Results-Presentation-for-FY2026.pdf) prints the same FY 2026 totals. IR: https://investors.csl.com/investors/financial-results-and-information

CSL Seqirus Revenue by Product (Annual) (USD millions)
PeriodAdjuvanted egg-based (FLUAD)Cell culture (FLUCELVAX)Standard egg-basedPandemic reservation feesPre-pandemic salesOther (including in-license)
FY 202696850310718361170
FY 2025901474116179197218
FY 20241,04053514017259122

Source: CSL Annual Report 2026 Note 2 (https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2026.pdf): FY 2026 / FY 2025 adjuvanted egg-based 968 / 901, cell culture 503 / 474, egg-based 107 / 116, pandemic reservation fees 183 / 179, pre-pandemic sales 61 / 197, other (including in-license) 170 / 218. Annual Report 2025 Note 2 (https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2025.pdf) restates FY 2024: adjuvanted 1,040, cell culture 535, egg-based 140, pandemic reservation 172, pre-pandemic 59, other 122. FY 2026 results presentation Appendix B (https://investors.csl.com/pdf/3d18fc4f-6133-41c7-9188-ec992e930ca3/Platform/ListPage/CSL-Results-Presentation-for-FY2026.pdf) prints FLUAD 968, FLUCELVAX 503, egg-based 107, and pandemic reservation fees 183.

CSL Vifor Revenue by Therapy (Annual) (USD millions)
PeriodIronNephrology dialysisNephrology non-dialysisOther Vifor
FY 20269151,03633075
FY 20251,03487126753
FY 20241,01878620049
FY 20231,00977113668

Source: CSL Annual Report 2026 Note 2 (https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2026.pdf): FY 2026 / FY 2025 iron 915 / 1,034, nephrology dialysis 1,036 / 871, nephrology non-dialysis 330 / 267, other 75 / 53. Annual Report 2025 Note 2 (https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2025.pdf): FY 2025 / FY 2024 iron 1,034 / 1,018, dialysis 871 / 786, non-dialysis 267 / 200, other 53 / 49. Annual Report 2024 Note 2 (https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2024.pdf and https://investors.csl.com/annualreport/2024/118/): FY 2024 / FY 2023 iron 1,018 / 1,009, dialysis 786 / 771, non-dialysis 200 / 136, other 49 / 68. FY 2026 results presentation Appendix B (https://investors.csl.com/pdf/3d18fc4f-6133-41c7-9188-ec992e930ca3/Platform/ListPage/CSL-Results-Presentation-for-FY2026.pdf) prints the same FY 2026 therapy totals for iron, dialysis, and non-dialysis.

Ask Sterling

Register for a premium account to gain access to Sterling AI.

Get Started

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving EV industry growth?
Menu
Favorites
CSL (CSL.AX) - KPIs | Sterling